KCT0005627进行中(未招募)未知
A Multicenter, Randomized, Active-controlled, Exploratory Clinical Trial study to evaluate the efficacy and safety of navigation guided balloon Eustachian tuboplasty for patients with chronic Eustachian tube dysfunction
Mega Medical0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 75(Year)(—)
- 性别
- All
入选标准
- •* Subjects must meet all the following criteria.
- •(1) Male or female over the age of 19
- •(2) Chronic Eustachian tube dysfunction patients with one or more of the criteria below
- •a) Those who have three or more of the following symptoms for 12 months or longer; ear pain, ear pressure, tinnitus, cracking or popping in ears, muffled hearing, feeling that ears are clogged.
- •b) Those with otitis media with effusion whose symptoms persist even after medication.
- •c) Those with adhesive otitis media whose symptoms persist even after medication.
- •(3) Patients who voluntarily agreed in writing to participate in this clinical trial.
排除标准
- •* Subjects who meet any of the following criteria cannot participate in this study.
- •(1) Those with proved dehiscence of internal carotid artery near the Eustachian tube in computed tomography (CT) scan.
- •(2) Patients with patulous Eustachian tube.
- •(3) Patients with tympanic membrane perforation or ventilation tube insertion state.
- •(4) Patients who have Meniere’s disease or chronic sinusitis.
- •(5) Those who have anatomy that are difficult for transnasal-approach to Eustachian tube.
- •(6) Those who have history of major head or neck surgery within 4 months.
- •(7) Patients with active chronic or acute otitis media.
- •(8) Pregnant, nursing, or childbearing-age women that have plan to get pregnant during the study period.
- •(9) Those with clinically significant liver disease (ALT or AST results are more than 2.5~3 times the normal upper limit in screening test).
- •(10) Those with clinically significant kidney disease (serum Creatinine result is more than 2.0 mg/dL in screening test) or with hemodialysis.
- •(11) Those who have history of malignancy including leukemia and lymphoma within past 5 years.
- •(12) Those who have experience of other clinical trial within past 4 weeks before this study.
- •(13) In case that researcher judged that participation in this clinical trial is not appropriate.
研究者
相似试验
进行中(未招募)
1 期
A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersParkinson's diseaseEUCTR2018-004156-37-BEeuroDerm Ltd.482
进行中(未招募)
1 期
A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)Parkinson's diseaseEUCTR2018-004156-37-CZeuroDerm Ltd.482
招募中
3 期
A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson's disease (BouNDless)Parkinson's disease2024-511940-20-00Neuroderm Ltd.156
进行中(未招募)
1 期
A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersParkinson's diseaseEUCTR2018-004156-37-HUeuroDerm Ltd.350
进行中(未招募)
1 期
A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersParkinson's diseaseEUCTR2018-004156-37-GBeuroDerm Ltd.350
